ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB – Get Free Report) saw a significant increase in short interest in the month of September. As of September 30th, there was short interest totaling 7,709 shares, an increase of 85.9% from the September 15th total of 4,147 shares. Based on an average trading volume of 5,937 shares, the short-interest ratio is currently 1.3 days. Currently, 0.9% of the shares of the company are short sold.
Institutional Investors Weigh In On ProShares Ultra Nasdaq Biotechnology
A hedge fund recently bought a new stake in ProShares Ultra Nasdaq Biotechnology stock. Toth Financial Advisory Corp purchased a new position in shares of ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB – Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,022 shares of the exchange traded fund’s stock, valued at approximately $118,000. Toth Financial Advisory Corp owned approximately 0.12% of ProShares Ultra Nasdaq Biotechnology as of its most recent filing with the Securities and Exchange Commission (SEC).
ProShares Ultra Nasdaq Biotechnology Stock Up 3.1%
NASDAQ BIB opened at $106.82 on Thursday. The firm has a 50-day moving average price of $113.40 and a two-hundred day moving average price of $97.44. ProShares Ultra Nasdaq Biotechnology has a 12-month low of $65.01 and a 12-month high of $126.40. The company has a market capitalization of $89.73 million, a P/E ratio of 20.68 and a beta of 1.20.
ProShares Ultra Nasdaq Biotechnology Company Profile
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day.
Featured Articles
- Five stocks we like better than ProShares Ultra Nasdaq Biotechnology
- Tesla Wants to Make Its Own Chips—What Could Go Wrong?
- IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
- PBF Energy’s Stunning Rally Faces a Critical Test
- Citi Stock Falls Despite Earnings Beat: What Investors Need to Know
Receive News & Ratings for ProShares Ultra Nasdaq Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares Ultra Nasdaq Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
